Xeris Biopharma Holdings, Inc.
XERS
$8.48
-$0.05-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 335.41M | 314.85M | 291.85M | 266.14M | 246.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 335.41M | 314.85M | 291.85M | 266.14M | 246.03M |
| Cost of Revenue | 45.03M | 44.42M | 42.57M | 41.10M | 43.70M |
| Gross Profit | 290.39M | 270.44M | 249.28M | 225.04M | 202.33M |
| SG&A Expenses | 208.14M | 191.50M | 182.37M | 175.01M | 173.52M |
| Depreciation & Amortization | 10.84M | 10.84M | 10.84M | 10.84M | 10.84M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 298.82M | 278.95M | 266.95M | 256.34M | 255.85M |
| Operating Income | 36.59M | 35.90M | 24.90M | 9.80M | -9.82M |
| Income Before Tax | -17.17M | 12.01M | 554.00K | -15.64M | -35.32M |
| Income Tax Expenses | -- | -- | -- | 0.00 | -3.32M |
| Earnings from Continuing Operations | -17.17 | 12.01 | 0.55 | -15.64 | -32.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.17M | 12.01M | 554.00K | -15.64M | -32.00M |
| EBIT | 36.59M | 35.90M | 24.90M | 9.80M | -9.82M |
| EBITDA | 48.77M | 48.08M | 37.05M | 21.94M | 2.28M |
| EPS Basic | -0.10 | 0.07 | 0.00 | -0.10 | -0.21 |
| Normalized Basic EPS | 0.05 | 0.04 | 0.00 | -0.06 | -0.15 |
| EPS Diluted | -0.10 | 0.07 | 0.00 | -0.10 | -0.22 |
| Normalized Diluted EPS | 0.05 | 0.04 | 0.00 | -0.06 | -0.15 |
| Average Basic Shares Outstanding | 672.96M | 659.59M | 641.52M | 624.65M | 609.99M |
| Average Diluted Shares Outstanding | 708.14M | 694.78M | 669.59M | 638.62M | 609.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |